RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li
Formato:	Artigo
Idioma:	English
Publicado em:	Elsevier 2024-02-01
coleção:	Neoplasia: An International Journal for Oncology Research
Assuntos:	Triple negative breast cancer Chemoresistance Cancer stem cells RUNX2 TGF-β
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1476558624000046

Registros relacionados

RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
por: Wentao Si, et al.
Publicado em: (2022-11-01)

RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
por: Natalia B. Fernández, et al.
Publicado em: (2023-01-01)

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
por: Bradley A. Hancock, et al.
Publicado em: (2019-08-01)

Comprehensive Analysis of RUNX and TGF-β Mediated Regulation of Immune Cell Infiltration in Breast Cancer
por: Liang Gao, et al.
Publicado em: (2021-08-01)

TGF-β induced reprogramming and drug resistance in triple-negative breast cells
por: Guoyu Wu, et al.
Publicado em: (2022-04-01)

CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death
por: Alexander H. Chung, et al.
Publicado em: (2019-02-01)

DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition
por: Jianbo Zheng, et al.
Publicado em: (2018-04-01)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Meng Wang, et al.
Publicado em: (2021-10-01)

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers
por: Anuradha Illendula, et al.
Publicado em: (2016-06-01)

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
por: Margarite D. Matossian, et al.
Publicado em: (2019-03-01)

Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer
por: Adam Hermawan, et al.
Publicado em: (2019-12-01)

The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context
por: Adiba S. Khan, et al.
Publicado em: (2023-02-01)

Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer
por: Shen-Jun Yuan, et al.
Publicado em: (2019-10-01)

B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer
por: Ling Wang, et al.
Publicado em: (2018-07-01)

A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
por: Hitesh Kumar, et al.
Publicado em: (2023-12-01)

miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A
por: Liu C, et al.
Publicado em: (2020-12-01)

A clinicopathologic study of triple negative breast cancer
por: Vandana L Gaopande, et al.
Publicado em: (2015-01-01)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Nicholas R. Hum, et al.
Publicado em: (2022-07-01)

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC
por: Andrew Sulaiman, et al.
Publicado em: (2021-10-01)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Alaa M. Ghallab, et al.
Publicado em: (2022-04-01)

Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer
por: Lei Di, et al.
Publicado em: (2019-03-01)

TUFT1 promotes metastasis and chemoresistance in triple negative breast cancer through the TUFT1/Rab5/Rac1 pathway
por: Weiguang Liu, et al.
Publicado em: (2019-09-01)

RUNX regulated immune-associated genes predicts prognosis in breast cancer
por: Jingyue Fu, et al.
Publicado em: (2022-08-01)

M6A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer
por: Xi Liu, et al.
Publicado em: (2024-02-01)

CD74-AKT Axis Is a Potential Therapeutic Target in Triple-Negative Breast Cancer
por: Jingchao Wang, et al.
Publicado em: (2024-06-01)

Role of eIF4A1 in triple‐negative breast cancer stem‐like cell‐mediated drug resistance
por: Dayanidhi Raman, et al.
Publicado em: (2022-12-01)

Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines
por: Ammar Said Suliman, et al.
Publicado em: (2021-01-01)

Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
por: Yen-Dun Tony Tzeng, et al.
Publicado em: (2018-11-01)

TUFT1 Promotes Triple Negative Breast Cancer Metastasis, Stemness, and Chemoresistance by Up-Regulating the Rac1/β-Catenin Pathway
por: Weiguang Liu, et al.
Publicado em: (2019-07-01)

Current approaches in treatment of triple-negative breast cancer
por: Hanan Ahmed Wahba, et al.
Publicado em: (2015-06-01)

Triple-Negative Breast Cancer Survival in Iranian Patients
por: Mahdi Aghili, et al.
Publicado em: (2013-08-01)

Platinum chemotherapy for early triple-negative breast cancer
por: Sofia RE. Mason, et al.
Publicado em: (2024-06-01)

Does triple negative breast cancer subtype carry poorer prognosis as compared to non-triple negative breast cancer lesion - A study from a tertiary hospital
por: Srijan Basu, et al.
Publicado em: (2023-11-01)

Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
por: Omran Saifi, et al.
Publicado em: (2022-04-01)

USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1
por: Yueh-Te Lin, et al.
Publicado em: (2022-10-01)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Elizabeth R. Berger, et al.
Publicado em: (2021-08-01)

Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
por: Magdalena Niedolistek, et al.
Publicado em: (2020-04-01)

Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells
por: Lisa Agnello, et al.
Publicado em: (2023-07-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
por: Mohammed Amrallah A., et al.
Publicado em: (2021-05-01)

The Adipokine Visfatin Modulates Cancer Stem Cell Properties in Triple-Negative Breast Cancer
por: Yi-Fen Chiang, et al.
Publicado em: (2023-01-01)